{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:16:45Z","timestamp":1791343005553,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009036","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,8,3]],"date-time":"2014-08-03T00:00:00Z","timestamp":1407024000000}}],"reference-count":114,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009036.pub2","type":"journal-article","created":{"date-parts":[[2014,8,3]],"date-time":"2014-08-03T16:35:19Z","timestamp":1407083719000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients"],"prefix":"10.1002","volume":"2014","author":[{"given":"Laurence","family":"Le Cleach","sequence":"first","affiliation":[{"name":"H\u00f4pital Henri Mondor; Department of Dermatology; 51 avenue du G\u00e9n\u00e9ral de Lattre de Tassigny Cr\u00e9teil France 94010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Trinquart","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu; French Cochrane Center; 1 place du Parvis Notre-Dame Paris France 75004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giao","family":"Do","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor; Department of Dermatology; 51 avenue du G\u00e9n\u00e9ral de Lattre de Tassigny Cr\u00e9teil France 94010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Maruani","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Fran\u00e7ois-Rabelais de Tours; Department of Dermatology; Tours France 37044"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9-salp\u00e9tri\u00e8re; Department of pharmacology; 47-83, boulevard de l?H\u00f4pital Paris France 75651 Cedex 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu; Universit\u00e9 Paris Descartes; INSERM U738; Centre d'Epid\u00e9miologie Clinique; 1, place du Parvis Notre-Dame Paris France 75004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chosidow","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor; Department of Dermatology; 51 avenue du G\u00e9n\u00e9ral de Lattre de Tassigny Cr\u00e9teil France 94010"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,3]]},"reference":[{"key":"10.1002\/14651858.CD009036.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Blom I Back O Egelrud T Frodin T Hellbe L Johannisson G Long-term oral acyclovir treatment prevents recurrent genital herpes Dermatologica 1986 220 3","DOI":"10.1159\/000249257"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Diaz-Mitoma F Sibbald R G Shafran S D Boon R Saltzman R L Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group JAMA 1998 887 92","DOI":"10.1001\/jama.280.10.887"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Douglas J M Critchlow C Benedetti J Mertz G J Connor J D Hintz M A A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection New England Journal of Medicine 1984 1551 6","DOI":"10.1056\/NEJM198406143102402"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0005|cit4","unstructured":"HS2100273. A randomized , double-blind, placebo-controlled,multicenter 60-day study comparing the efficacy of valtrex 1gr once daily vs placebo once daily in reducing viral shedding in immunocompetent subjects with recurrent HSV_2 genital herpes gsk-clinicalstudyregister.com 2005"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0004|cit5","doi-asserted-by":"crossref","unstructured":"Fife KH Warren TJ Ferrera RD Young DG Justus SE Heitman CK Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial Mayo Clinic Proceedings. Mayo Clinic 2006 1321 7","DOI":"10.4065\/81.10.1321"},{"issue":"22","key":"10.1002\/14651858.CD009036.pub2-BIB0006|cit6","first-page":"1817","article-title":"Suppression of recurrent genital herpes by oral application of acyclovir","volume":"60","author":"Halsos","year":"1985","journal-title":"H+G Zeitschrift fur Hautkrankheiten"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2340\/00015555655963","article-title":"Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study","volume":"65","author":"Halsos","year":"1985","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0008|cit8","unstructured":"A multicenter , double blind, placebo-controlled trial to evaluate daily suppressive therapy with Valtrex on the rate of HSV shedding in subject with recurrent genital herpes gsk-clinicalstudyregister.com 2005"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Kinghorn G R Jeavons M Rowland M Abeywickreme I Barton I G Potter C W Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study Genitourinary Medicine 1985 387 90","DOI":"10.1136\/sti.61.6.387"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Kinghorn GR Woolley PD Thin RN De Maubeuge J Foidart JM Engst R Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection Genitourinary Medicine 1992 312 6","DOI":"10.1136\/sti.68.5.312"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0011|cit11","unstructured":"Kroon S Petersen CS Andersen LP Rasmussen LP Vestergaard BF Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study Danish Medical Bulletin 1989 298 300"},{"issue":"4","key":"10.1002\/14651858.CD009036.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/infdis\/164.4.753","article-title":"A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes","volume":"164","author":"Clive","year":"1991","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0013|cit13","unstructured":"Mattison HR Reichman RC Benedetti J Bolgiano D Davis LG Bailey-Farchione A Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes American Journal of Medicine 1988 20 5"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0015|cit14","first-page":"24A-31A; discus","article-title":"Long-term suppressive therapy with acyclovir for recurrent genital herpes","volume":"22 Suppl 1","author":"Baker","year":"1994","journal-title":"Journal of International Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0014|cit15","first-page":"84","article-title":"One-year suppression of frequent recurrences of genital herpes with oral acyclovir","volume":"73","author":"Baker","year":"1989","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jmv.1890260106","article-title":"Effects of long-term acyclovir chemosuppression on serum IgG antibody to herpes simplex virus","volume":"26","author":"Erlich","year":"1988","journal-title":"Journal of Medical Virology"},{"issue":"6","key":"10.1002\/14651858.CD009036.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/infdis\/169.6.1338","article-title":"Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group","volume":"169","author":"Fife","year":"1994","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Goldberg LH Kaufman R Kurtz TO Conant MA Eron L J Batenhorst RL Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group Archives of Dermatology 1993 582 7","DOI":"10.1001\/archderm.1993.01680260052005"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Goldberg LH Kaufman RH Kurtz TO Conant MA Eron L J Batenhorst RL Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir Journal of Medical Virology 1993 45 50","DOI":"10.1002\/jmv.1890410510"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Kaplowitz LG Baker D Gelb L Blythe J Hale R Frost P Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group JAMA 1991 747 51","DOI":"10.1001\/jama.1991.03460060079028"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0021|cit21","unstructured":"Mertz GJ Eron L Kaufman R Goldberg L Raab B Conant M Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection American Journal of Medicine 1988 14 9"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Mertz GJ Jones CC Mills J Fife KH Lemon SM Stapleton JT Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial JAMA 1988 201 6","DOI":"10.1001\/jama.1988.03410020067030"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Mertz GJ Loveless MO Levin MJ Kraus SJ Fowler SL Goade D Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group Archives of Internal Medicine 1997 343 9","DOI":"10.1001\/archinte.1997.00440240109016"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Mindel A Weller IV Faherty A Sutherland S Hindley D Fiddian AP Prophylactic oral acyclovir in recurrent genital herpes Lancet 1984 57 9","DOI":"10.1016\/S0140-6736(84)90237-X"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0025|cit25","unstructured":"Mostow SR Mayfield JL Marr JJ Drucker JL Suppression of recurrent genital herpes by single daily dosages of acyclovir American Journal of Medicine 1988 30 3"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0026|cit26","unstructured":"123-037 gsk-clinicalstudyregister.com 2005"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Patel R Bodsworth NJ Woolley P Peters B Vejlsgaard G Saari S Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group Genitourinary Medicine 1997 105 9","DOI":"10.1136\/sti.73.2.105"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0028|cit28","unstructured":"Multicentre randomised trial comparing two strategies for the episodic use of valacyclovir , alone or combined with suppressive treatment in immunocompetent patients with recurrent genital herpes gsk-clinicalstudyregister.com 2006"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0029|cit29","unstructured":"123-026 gsk-clinicalstudyregister.com 2005"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Patel R Tyring S Strand A Price MJ Grant DM Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection Sexually Transmitted Infections 1999 398 402","DOI":"10.1136\/sti.75.6.398"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Reitano M Tyring S Lang W Thoming C Worm A M Borelli S Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group Journal of Infectious Diseases 1998 603 10","DOI":"10.1086\/515385"},{"issue":"3","key":"10.1002\/14651858.CD009036.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007435-200303000-00010","article-title":"Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study","volume":"30","author":"Romanowski","year":"2003","journal-title":"Sexually Transmitted Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Taback NA Bradley C Validation of the genital herpes treatment satisfaction questionnaire (GHerpTSQ) in status and change versions Quality of Life Research 2006 1043 52","DOI":"10.1007\/s11136-006-0048-2"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Sacks SL Fox R Levendusky P Stiver HG Roland S Nusinoff-Lehrman S Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes Sexually Transmitted Diseases 1988 58 62","DOI":"10.1097\/00007435-198801000-00013"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Sacks SL Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial Journal of Infectious Diseases 2004 1341 7","DOI":"10.1086\/383038"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009036.pub2-BIB0036|cit36","first-page":"43","article-title":"Efficacy of long-term suppressive therapy with valacyclovir in recurrent genital herpes","volume":"10","author":"Sekhin","year":"2004","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0037|cit37","unstructured":"Straus SE Seidlin M Takiff HE BachrachS DiGiovanna JJ Western KA Suppression of recurrent genital herpes with oral acyclovir Transactions of the Association of American Physicians 1983 278 83"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Straus SE Takiff HE Seidlin M Bachrach S Lininger L DiGiovanna JJ Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir New England journal of medicine 1984 1545 50","DOI":"10.1056\/NEJM198406143102401"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Thin R N Jeffries DJ Taylor PK Ayra OP Rodin P Yeo J Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial Journal of Antimicrobial Chemotherapy 1985 219 26","DOI":"10.1093\/jac\/16.2.219"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0040|cit40","unstructured":"Velasco M Saavedra T Sepulveda C Suarez M [Prolonged treatment with acyclovir in recurrent genital herpes. Clinical, virological, and immunological response] Revista Medica de Chile 1991 876 80"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Wald A Selke S Warren T Aoki FY Sacks S Diaz-Mitoma F Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding Sexually Transmitted Diseases 2006 529 33","DOI":"10.1097\/01.olq.0000204723.15765.91"},{"issue":"9","key":"10.1002\/14651858.CD009036.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.olq.0000204723.15765.91","article-title":"Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding","volume":"33","author":"Wald","year":"2006","journal-title":"Sexually Transmitted Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0044|cit43","unstructured":"CFAM 810AU07 Novartis clinical trial database (www.novctrd.com)"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0043|cit44","doi-asserted-by":"crossref","unstructured":"Bartlett BL Tyring SK Fife K Gnann JW Jr Hadala JT Kianifard F Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial Journal of Clinical Virology 2008 190 5","DOI":"10.1016\/j.jcv.2008.06.004"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Celum C Wald A Hughes J Sanchez J Reid S Delany-Moretlwe S Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial Lancet 2008 2109 19","DOI":"10.1016\/S0140-6736(08)60920-4"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Corey L Wald A Patel R Sacks S Tyring SK Warren T Once-daily valacyclovir to reduce the risk of transmission of genital herpes New England Journal of Medicine 2004 11 20","DOI":"10.1056\/NEJMoa035144"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Kim HN Wald A Harris J Almekinder J Heitman C Corey L Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study Sexually Transmitted Diseases 2008 124 8","DOI":"10.1097\/OLQ.0b013e31815407d7"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Fife KH Almekinder J Ofner S A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir Sexually Transmitted Diseases 2007 297 301","DOI":"10.1097\/01.olq.0000237853.69443.71"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Fuchs J Celum C Wang J Hughes J Sanchez J Cowan F Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial Journal of Infectious Diseases 2010 1164 8","DOI":"10.1086\/651381"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Gold D Ashley R Solberg G Abbo H Corey L Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins Journal of Infectious Diseases 1988 1227 34","DOI":"10.1093\/infdis\/158.6.1227"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Gupta R Wald A Krantz E Selke S Warren T Vargas-Cortes M Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract Journal of Infectious Diseases 2004 1374 81","DOI":"10.1086\/424519"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0052|cit52","unstructured":"A randomized, double-blind, multicenter study of valtrex 500mg suppressive therapy in the reduction of anxiety associated with recurrent genital herpes gsk-clinicalstudyregister.com"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0053|cit53","unstructured":"A randomized, double-blind, multicenter study of Valtrex 500mg Suppressive therapy in the reduction of anxiety associated with recurrent genital herpes gsk-clinicalstudyregister.com"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1136\/sextrans-2011-050109.128","article-title":"Frequent breakthrough genital HSV-2 shedding on standard and high dose valacyclovir","volume":"87","author":"Johnston","year":"2011","journal-title":"Sexually Transmitted Infections"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Johnston C Saracino M Kuntz S Magaret A Selke S Huang ML Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials Lancet 2012 641 7","DOI":"10.1016\/S0140-6736(11)61750-9"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Leone P Warren T Hamed K Fife K Wald A Famciclovir reduces viral mucosal shedding in HSV-seropositive persons Sexually Transmitted Diseases 2007 900 7","DOI":"10.1097\/OLQ.0b013e318063c749"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Mindel A Faherty A Carney O Patou G Freris M Williams P Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes Lancet 1988 926 8","DOI":"10.1016\/S0140-6736(88)91725-4"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Mindel A Carney O Sonnex C Freris M Patou G Williams P Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex Genitourinary Medicine 1989 103 5","DOI":"10.1136\/sti.65.2.103"},{"issue":"11","key":"10.1002\/14651858.CD009036.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/jac\/dkr346","article-title":"Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy","volume":"66","author":"Schiffer","year":"2011","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Strachan E Saracino M Selke S Magaret A Buchwald D Wald A The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women Brain, Behavior, and Immunity 2011 1475 81","DOI":"10.1016\/j.bbi.2011.06.003"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Straus SE Seidlin M Takiff HE Rooney J F Lehrman S N Bachrach S Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes Antiviral Research 1986 151 9","DOI":"10.1016\/0166-3542(86)90009-4"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Gupta R Hill EL McClernon D Davis G Selke S Corey L Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women Journal of Infectious Diseases 2005 1102 7","DOI":"10.1086\/432766"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD009036.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-124-1_Part_1-199601010-00002","article-title":"Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir","volume":"124","author":"Wald","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Watson-Jones D Weiss HA Rusizoka M Changalucha J Baisley K Mugeye K Effect of herpes simplex suppression on incidence of HIV among women in Tanzania New England Journal of Medicine 2008 1560 71","DOI":"10.1056\/NEJMoa0800260"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Douglas JM Jr Davis LG Remington ML Paulsen CA Perrin EB Goodman P A double-blind, placebo-controlled trial of the effect of chronically administered oral acyclovir on sperm production in men with frequently recurrent genital herpes Journal of Infectious Diseases 1988 588 93","DOI":"10.1093\/infdis\/157.3.588"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Frenkel L Pineda E Garratty E Fall H Dillon M Bryson Y A prospective study of the effects of acyclovir treatment on the HSV-2 lymphoproliferative response of persons with frequently recurring HSV-2 genital infections Journal of Infectious Diseases 1989 845 50","DOI":"10.1093\/infdis\/159.5.845"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0067|cit67","unstructured":"Mastrolorenzo A Zuccati G Tiradritti L Brandini L Filippeschi C Panconesi E [Treatment of recurrent herpes simplex genitalis] Giornale Italiano di Chemioterapia 1991 61 2"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Tyring SK Diaz-Mitoma F Shafran SD Locke LA Sacks SL Young CL Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials Journal of Cutaneous Medicine and Surgery 2003 449 54","DOI":"10.1177\/120347540300700603"},{"issue":"6","key":"10.1002\/14651858.CD009036.pub2-BIB0069|cit69","first-page":"475","article-title":"A randomized controlled clinical study on valaciclovir in the treatment of recurrent genital herpes in different course of treatment","volume":"25","author":"Wu","year":"2000","journal-title":"Chinese Journal of Antibiotics"},{"issue":"4","key":"10.1002\/14651858.CD009036.pub2-BIB0070|cit70","first-page":"213","article-title":"To comparative the effect of aciclovir and valaciclovir on preventing the recurrence of recurrent genital herpes","volume":"40","author":"Zhang","year":"2011","journal-title":"Journal of Clinical Dermatology"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0071|cit71","unstructured":"Safety and efficacy comparator trial of a new drug against genital herpes Ongoing study October 2012"},{"issue":"5","key":"10.1002\/14651858.CD009036.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/590561","article-title":"Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial","volume":"47","author":"Abudalu","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/498521","article-title":"Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Aoki","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD009036.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/0003-4819-121-11-199412010-00004","article-title":"Recurrence rates in genital herpes after symptomatic first-episode infection","volume":"121","author":"Benedetti","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1185\/03007990802664678","article-title":"Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance","volume":"25","author":"Bodsworth","year":"2009","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD009036.pub2-BIB0076|cit76","first-page":"447","article-title":"Genital herpes and human immunodeficiency virus: double trouble","volume":"82","author":"Celum","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0077|cit77","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD009036.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/sim.1206","article-title":"Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"Clercq","year":"2006","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00007435-200302000-00015","article-title":"Natural history of genital herpes simplex virus type 1 infection","volume":"30","author":"Engelberg","year":"2003","journal-title":"Sexually Transmitted Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Patel R Alderson S Geretti A 2010 European guideline for management of genital herpes http:\/\/www.iusti.org\/regions\/Europe\/euroguidelines.htm (accessed September 2010)","DOI":"10.1258\/ijsa.2010.010278"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS (London, England)"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD009036.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0190-9622(86)70165-5","article-title":"Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety","volume":"15","author":"Goldberg","year":"1986","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9605","key":"10.1002\/14651858.CD009036.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0086|cit86","first-page":"CD004946","article-title":"Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection","volume":"1","author":"Hollier","year":"2008","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"7626","key":"10.1002\/14651858.CD009036.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","article-title":"Uncertainty in heterogeneity estimates in meta-analyses","volume":"335","author":"Ioannidis","year":"2007","journal-title":"BMJ (Clinical research ed.)"},{"issue":"8","key":"10.1002\/14651858.CD009036.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"Canadian Medical Association Journal"},{"issue":"19","key":"10.1002\/14651858.CD009036.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1056\/NEJMcp023065","article-title":"Clinical practice. Genital herpes","volume":"350","author":"Kimberlin","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1542\/peds.2012-3216","article-title":"Guidance on management of asymptomatic neonates born to women with active genital herpes lesions","volume":"131","author":"Kimberlin","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaad.2007.02.008","article-title":"A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks","volume":"57","author":"Lebrun-Vignes","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD009036.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/339326","article-title":"Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment","volume":"34","author":"Leone","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD009036.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"805-12, A","DOI":"10.2471\/BLT.07.046128","article-title":"An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection","volume":"86","author":"Looker","year":"2008","journal-title":"Bulletin of the World Health Organization"},{"issue":"20","key":"10.1002\/14651858.CD009036.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"13","key":"10.1002\/14651858.CD009036.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archinternmed.2009.177","article-title":"A pooled analysis of the effect of condoms in preventing HSV-2 acquisition","volume":"169","author":"Martin","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"15","key":"10.1002\/14651858.CD009036.pub2-BIB0096|cit96","first-page":"456","article-title":"Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-9-2","article-title":"Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study","volume":"9","author":"Moreno","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"16","key":"10.1002\/14651858.CD009036.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1001\/jama.1984.03340400031020","article-title":"Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial","volume":"251","author":"Reichman","year":"1984","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD009036.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","article-title":"Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group","volume":"14","author":"Romanowski","year":"2000","journal-title":"AIDS (London, England)"},{"issue":"5","key":"10.1002\/14651858.CD009036.pub2-BIB0100|cit100","first-page":"399","article-title":"Acyclovir: evaluation of a new antiviral agent","volume":"1","author":"Rosenberry","year":"1982","journal-title":"Clinical Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD009036.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/biostatistics\/kxq046","article-title":"Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis","volume":"12","author":"Rucker","year":"2011","journal-title":"Biostatistics (Oxford, England)"},{"issue":"8","key":"10.1002\/14651858.CD009036.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1086\/444457","article-title":"Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial","volume":"41","author":"Sacks","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD009036.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/44.4.525","article-title":"A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group","volume":"44","author":"Saiag","year":"1999","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD009036.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/sti.78.3.160","article-title":"Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision","volume":"78","author":"Scoular","year":"2002","journal-title":"Sexually Transmitted Infections"},{"issue":"7602","key":"10.1002\/14651858.CD009036.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bmj.39189.504306.55","article-title":"Genital herpes and its management","volume":"334","author":"Sen","year":"2007","journal-title":"BMJ (Clinical research ed.)"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1096-9071(199806)55:2<177::AID-JMV15>3.0.CO;2-F","article-title":"A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes","volume":"55","author":"Slomka","year":"1998","journal-title":"Journal of medical virology"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1741-7015-10-68","article-title":"Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions","volume":"10","author":"Tran","year":"2012","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2288-12-150","article-title":"Adjustment for reporting bias in network meta-analysis of antidepressant trials","volume":"12","author":"Trinquart","year":"2012","journal-title":"BMC Medical Research Methodoly"},{"issue":"14","key":"10.1002\/14651858.CD009036.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD009036.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archderm.134.2.185","article-title":"A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group","volume":"134","author":"Tyring","year":"1998","journal-title":"Archives of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD009036.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/339325","article-title":"Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection","volume":"34","author":"Wald","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD009036.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1086\/422362","article-title":"Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV","volume":"39 Suppl 5","author":"Warren","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"9267","key":"10.1002\/14651858.CD009036.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009036.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:47:41Z","timestamp":1713347261000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009036.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane STI Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,3]]},"references-count":114,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009036.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,3]]}}}